In a recent report on MediJean’s news section, a primer on cannabinoid receptor type 2 (CB2) reveals the science behind this important compound integral to patients.
CB2 was first discovered in the spleen in 1993 and is mostly concentrated in the closely linked peripheral nervous system and immune system. “This location accounts for marijuana’s effects on inflammatory bowel diseases, such as Crohn’s and ulcerative colitis, and its potential to treat chronic pain.
Elsewhere in the body, marijuana has also been shown to be effective in treating osteoporosis via the CB2 receptor,” as the MediJean report states.
At the University of Auckland, researcher Michelle Glass found that the CB2 receptor could play a role in protecting neurons from losing the insulating layer, or myelin, which surrounds them and allows their electric signals to be transmitted.
“CB2 may provide a novel target for a range of neuropathologies,” her paper stated.
Research is also being done on CB2’s role in treating other “demyelinating” diseases. In 2013, Spanish researchers reported that cannabinoids could protect neurons from the damaging effects of neurodegenerative disorders like Parkinson’s disease. Their study was funded in part by the Michael J. Fox Foundation.
For more info on CB2, go here.
VOTE in this poll below to share how knowledgeable you are about medical marijuana’s scientific compounds: